Brain Tumor News Update on Medicare Part D Changes

Printer Friendly

March 11, 2014

You may have read in our recent e-news that the ABTA signed on to the Regulatory Education and Action for Patients (REAP) letter commenting on the proposed changes to the Medicare Part D and the Medicare Prescription Drug Benefit Programs, in particular, the proposed elimination of some of the protected drug classes – among which are anticonvulsants and antidepressants.

We are pleased to share that within 24 hours of this letter being submitted, the Center for Medicare and Medicaid Services has revoked the proposed changes to Medicare Part D.

This is so important to brain tumor patients and their families, who need access to these drugs classes that may be critical to their care.

The ABTA is proud to serve as a voice for the brain tumor community on public policy and legislative issues as a member of key Washington D.C.-based advocacy groups whose efforts are aligned with the interests of our brain tumor constituents.